|
16
|
99
|
3zptA |
Design and synthesis of p1-p3 macrocyclic tertiary alcohol comprising hiv-1 protease inhibitors |
|
16
|
99
|
3zpsA |
Design and synthesis of p1-p3 macrocyclic tertiary alcohol comprising hiv-1 protease inhibitors |
|
15
|
99
|
4a6cA |
Stereoselective synthesis, x-ray analysis, and biological evaluation of a new class of lactam based hiv-1 protease inhibitors |
|
16
|
99
|
3zpuA |
Design and synthesis of p1-p3 macrocyclic tertiary alcohol comprising hiv-1 protease inhibitors |
|
15
|
99
|
4a4qA |
Stereoselective synthesis, x-ray analysis, and biological evaluation of a new class of lactam based hiv-1 protease inhibitors |
|
16
|
99
|
4a6bA |
Stereoselective synthesis, x-ray analysis, and biological evaluation of a new class of lactam based hiv-1 protease inhibitors |
|
18
|
116
|
3wsjA |
Htlv-1 protease in complex with the hiv-1 protease inhibitor indinavir |
|
18
|
99
|
3vf5A |
Crystal structure of hiv-1 protease mutant i47v with novel p1'-ligands grl-02031 |
|
18
|
99
|
3vf7A |
Crystal structure of hiv-1 protease mutant l76v with novel p1'-ligands grl-02031 |
|
17
|
99
|
3vfbA |
Crystal structure of hiv-1 protease mutant n88d with novel p1'-ligands grl-02031 |
|
18
|
99
|
3vfaA |
Crystal structure of hiv-1 protease mutant v82a with novel p1'-ligands grl-02031 |
|
16
|
99
|
3uf3A |
Crystal structure of multidrug resistant hiv-1 protease clinical isolate pr20 |
|
15
|
99
|
3upjA |
Human immunodeficiency virus type 2 protease mutant with lys 57 replaced by leu (k57l) complex with u096333 [4-hydroxy-3-[1-(phenyl)propyl]-7-methoxycoumarin] |
|
16
|
99
|
3ucbA |
Crystal structure of multidrug resistant hiv-1 protease clinical isolate pr20 in complex with darunavir |
|
19
|
99
|
3ufnA |
Crystal structure of multidrug resistant hiv-1 protease clinical isolate pr20 in complex with saquinavir |
|
16
|
99
|
3uhlA |
Crystal structure of multidrug resistant hiv-1 protease clinical isolate pr20 in complex with p2-nc substrate analog |
|
17
|
99
|
3u7sA |
Hiv pr drug resistant patient's variant in complex with darunavir |
|
16
|
99
|
3u71A |
Crystal structure analysis of south african wild type hiv-1 subtype c protease |
|
18
|
99
|
3ttpA |
Structure of multiresistant hiv-1 protease in complex with darunavir |
|
18
|
99
|
3togA |
Hiv-1 protease - epoxydic inhibitor complex (ph 9 - monoclinic crystal form p21) |
|
19
|
103
|
3tkgA |
Crystal structure of hiv model protease precursor/saquinavir complex |
|
17
|
99
|
3tofA |
Hiv-1 protease - epoxydic inhibitor complex (ph 6 - orthorombic crystal form p212121) |
|
16
|
99
|
3tkwA |
Crystal structure of hiv protease model precursor/darunavir complex |
|
17
|
99
|
3tlhA |
Structural studies of hiv and fiv proteases complexed withan efficient inhibitor of fiv pr |
|
18
|
99
|
3tl9A |
Crystal structure of hiv protease model precursor/saquinavir complex |
|
18
|
99
|
3tohA |
Hiv-1 protease - epoxydic inhibitor complex (ph 9 - orthorombic crystal form p212121) |
|
17
|
99
|
3th9A |
Crystal structure of hiv-1 protease mutant q7k v32i l63i with a cyclic sulfonamide inhibitor |
|
18
|
99
|
3t3cA |
Structure of hiv pr resistant patient derived mutant (comprising 22 mutations) in complex with drv |
|
14
|
99
|
3t11A |
Dimeric inhibitor of hiv-1 protease. |
|
19
|
99
|
3st5A |
Crystal structure of wild-type hiv-1 protease with c3-substituted hexahydrocyclopentafuranyl urethane as p2-ligand, grl-0489a |
|
23
|
114
|
3slzA |
The crystal structure of xmrv protease complexed with tl-3 |
|
20
|
113
|
3sm1A |
The crystal structure of xmrv protease complexed with pepstatin a |
|
23
|
95
|
3sqfA |
Crystal structure of monomeric m-pmv retroviral protease |
|
19
|
99
|
3spkA |
Tipranavir in complex with a human immunodeficiency virus type 1 protease variant |
|
15
|
99
|
3so9A |
Darunavir in complex with a human immunodeficiency virus type 1 protease variant |
|
21
|
114
|
3sm2A |
The crystal structure of xmrv protease complexed with amprenavir |
|
18
|
99
|
3sa9A |
Crystal structure of wild-type hiv-1 protease in complex with af68 |
|
18
|
99
|
3sabA |
Crystal structure of wild-type hiv-1 protease in complex with af78 |
|
18
|
99
|
3s53A |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug darunavir in space group p212121 |
|
18
|
99
|
3s43B |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug amprenavir |
|
16
|
99
|
3s45A |
Wild-type hiv-2 protease with antiviral drug amprenavir |
|
19
|
99
|
3s43A |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug amprenavir |
|
17
|
99
|
3s56A |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug saquinavir |
|
19
|
99
|
3s54A |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug darunavir in space group p21212 |
|
19
|
99
|
5wloA |
A novel 13-ring macrocyclic hiv-1 protease inhibitors involving the p1'-p2' ligands |
|
15
|
99
|
5w5wA |
Hiv protease (pr) in open form with mg2+ in active site and hive-9 in eye site |
|
17
|
99
|
5vckA |
Hiv protease (pr) with tl-3 in the active site and (z)-n-(thiazol-2-yl)-n'-tosylcarbamimidate in the exosite |
|
17
|
99
|
5veaA |
Hiv protease (pr) with tl-3 in active site and 4-methylbenzene-1,2-diamine in exosite |
|
19
|
99
|
5v4yA |
X-ray crystal structure of wild type hiv-1 protease in complex with grl-09510 |
|
19
|
99
|
5upzA |
Hiv-1 wild type protease with grl-0518a , an isophthalamide-derived p2-p3 ligand with the para-hydoxymethyl sulfonamide isostere as the p2' group |
